(n=6) remain disease-free more than two years after treatment; 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at ...

Medically reviewed by Gagandeep Brar, MD Key Takeaways Stage 4 prostate cancer is advanced and has spread beyond the prostate ...

According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™ an investigational in situ multi-target immunotherapy platform for solid tumors, today announced that ...

PSMA radio-guided surgery can detect metastatic lymph nodes that are missed by preoperative PSMA PET in patients with intermediate- and high-risk prostate cancer. In patients undergoing robot-assisted ...

Experimental oral drug JNJ-6143 produced strong PSA and tumor responses in patients with heavily treated advanced prostate ...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...